Search

Artificial neural networks (ANNs) ability to learn, correct errors, and transform a large amount of raw data into beneficial medical decisions for treatment and care has increased in popularity for enhanced patient safety and quality of care. Therefore, this paper reviews the critical role of ANNs in providing valuable insights for patients' healthcare decisions and efficient disease diagnosis. We study different types of ANNs in the existing literature that advance ANNs' adaptation for complex applications. Specifically, we investigate ANNs' advances for predicting viral, cancer, skin, and COVID-19 diseases. Furthermore, we propose a deep convolutional neural network (CNN) model called ConXNet, based on chest radiography images, to improve the detection accuracy of COVID-19 disease. ConXNet is trained and tested using a chest radiography image dataset obtained from Kaggle, achieving more than 97% accuracy and 98% precision, which is better than other existing state-of-the-art models, such as DeTraC, U-Net, COVID MTNet, and COVID-Net, having 93.1%, 94.10%, 84.76%, and 90% accuracy and 94%, 95%, 85%, and 92% precision, respectively. The results show that the ConXNet model performed significantly well for a relatively large dataset compared with the aforementioned models. Moreover, the ConXNet model reduces the time complexity by using dropout layers and batch normalization techniques. Finally, we highlight future research directions and challenges, such as the complexity of the algorithms, insufficient available data, privacy and security, and integration of biosensing with ANNs. These research directions require considerable attention for improving the scope of ANNs for medical diagnostic and treatment applications. [ABSTRACT FROM AUTHOR]

It has been validated beyond doubt that High-Resolution Computed Tomography (HRCT) chest and to some extent chest radiographs have a role in corona virus disease-19 (COVID-19). Much less is known about the role of lung ultrasonography (LUS) in COVID-19. In this paper, our main purpose was to gauge the relationship between LUS and chest HRCT in reverse transcriptase polymerase chain reaction (RT–PCR) documented cases of COVID-19, as well as in those with high suspicion of COVID-19 with negative RT–PCR. It was a prospective study carried out at our tertiary care hospital, namely, SKIMS Soura. The total number of patients in this study were 152 (200 patients were selected out of which only 152 had undergone both LUS and chest HRCT). The patients were subjected to both LUS and chest HRCT. The radiologist who performed LUS was blinded to clinical findings and HRCT was evaluated by a radiologist with about a decade of experience. The LUS findings compatible with the disease were subpleural consolidations, B-lines and irregular pleural lines. Findings that were compatible with COVID-19 on chest HRCT were bibasilar, subpleural predominant ground glass opacities, crazy paving and consolidations. COVID-19-positive patients were taken up for chest HRCT for disease severity stratification and were also subjected to LUS. On HRCT chest, the imaging abnormalities compatible with COVID-19 were evident in 110 individuals (72.37%), and on Lung Ultrasound they were observed in 120 individuals (78.95%). Imaging of COVID-19 patients assessed by both LUS and HRCT chest,, showed a positive correlation (p < 0.0001). The study revealed a sensitivity of 88%, a specificity of 76.62%, a positive predictive value of 78.57% and a negative predictive value of 86.76%. None of the individuals with a diagnosis of COVID-19 on HRCT were missed on LUS. An excellent correlation was derived between the LUS score and CT total severity score (p < 0.0001 with a kappa of 0.431). Similar precision compared with chest HRCT in the detection of chest flaws in COVID-19 patients was obtained on LUS. [ABSTRACT FROM AUTHOR]

The novel coronavirus (COVID-19) pandemic still has a significant impact on the worldwide population's health and well-being. Effective patient screening, including radiological examination employing chest radiography as one of the main screening modalities, is an important step in the battle against the disease. Indeed, the earliest studies on COVID-19 found that patients infected with COVID-19 present with characteristic anomalies in chest radiography. In this paper, we introduce COVID-ConvNet, a deep convolutional neural network (DCNN) design suitable for detecting COVID-19 symptoms from chest X-ray (CXR) scans. The proposed deep learning (DL) model was trained and evaluated using 21,165 CXR images from the COVID-19 Database, a publicly available dataset. The experimental results demonstrate that our COVID-ConvNet model has a high prediction accuracy at 97.43% and outperforms recent related works by up to 5.9% in terms of prediction accuracy. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic has sparked a barrage of primary research and reviews. We investigated the publishing process, time and resource wasting, and assessed the methodological quality of the reviews on artificial intelligence techniques to diagnose COVID-19 in medical images. We searched nine databases from inception until 1 September 2020. Two independent reviewers did all steps of identification, extraction, and methodological credibility assessment of records. Out of 725 records, 22 reviews analysing 165 primary studies met the inclusion criteria. This review covers 174,277 participants in total, including 19,170 diagnosed with COVID-19. The methodological credibility of all eligible studies was rated as critically low: 95% of papers had significant flaws in reporting quality. On average, 7.24 (range: 0–45) new papers were included in each subsequent review, and 14% of studies did not include any new paper into consideration. Almost three-quarters of the studies included less than 10% of available studies. More than half of the reviews did not comment on the previously published reviews at all. Much wasting time and resources could be avoided if referring to previous reviews and following methodological guidelines. Such information chaos is alarming. It is high time to draw conclusions from what we experienced and prepare for future pandemics. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic shed light on the need for quick diagnosis tools in healthcare, leading to the development of several algorithmic models for disease detection. Though these models are relatively easy to build, their training requires a lot of data, storage, and resources, which may not be available for use by medical institutions or could be beyond the skillset of the people who most need these tools. This paper describes a data analysis and machine learning platform that takes advantage of high-performance computing infrastructure for medical diagnosis support applications. This platform is validated by re-training a previously published deep learning model (COVID-Net) on new data, where it is shown that the performance of the model is improved through large-scale hyperparameter optimisation that uncovered optimal training parameter combinations. The per-class accuracy of the model, especially for COVID-19 and pneumonia, is higher when using the tuned hyperparameters (healthy: 96.5%; pneumonia: 61.5%; COVID-19: 78.9%) as opposed to parameters chosen through traditional methods (healthy: 93.6%; pneumonia: 46.1%; COVID-19: 76.3%). Furthermore, training speed-up analysis shows a major decrease in training time as resources increase, from 207 min using 1 node to 54 min when distributed over 32 nodes, but highlights the presence of a cut-off point where the communication overhead begins to affect performance. The developed platform is intended to provide the medical field with a technical environment for developing novel portable artificial-intelligence-based tools for diagnosis support. [ABSTRACT FROM AUTHOR]

This paper proposes a new deep learning (DL) framework for the analysis of lung diseases, including COVID-19 and pneumonia, from chest CT scans and X-ray (CXR) images. This framework is termed optimized DenseNet201 for lung diseases (LDDNet). The proposed LDDNet was developed using additional layers of 2D global average pooling, dense and dropout layers, and batch normalization to the base DenseNet201 model. There are 1024 Relu-activated dense layers and 256 dense layers using the sigmoid activation method. The hyper-parameters of the model, including the learning rate, batch size, epochs, and dropout rate, were tuned for the model. Next, three datasets of lung diseases were formed from separate open-access sources. One was a CT scan dataset containing 1043 images. Two X-ray datasets comprising images of COVID-19-affected lungs, pneumonia-affected lungs, and healthy lungs exist, with one being an imbalanced dataset with 5935 images and the other being a balanced dataset with 5002 images. The performance of each model was analyzed using the Adam, Nadam, and SGD optimizers. The best results have been obtained for both the CT scan and CXR datasets using the Nadam optimizer. For the CT scan images, LDDNet showed a COVID-19-positive classification accuracy of 99.36%, a 100% precision recall of 98%, and an F1 score of 99%. For the X-ray dataset of 5935 images, LDDNet provides a 99.55% accuracy, 73% recall, 100% precision, and 85% F1 score using the Nadam optimizer in detecting COVID-19-affected patients. For the balanced X-ray dataset, LDDNet provides a 97.07% classification accuracy. For a given set of parameters, the performance results of LDDNet are better than the existing algorithms of ResNet152V2 and XceptionNet. [ABSTRACT FROM AUTHOR]

A comprehensive medical image-based diagnosis is usually performed across various image modalities before passing a final decision; hence, designing a deep learning model that can use any medical image modality to diagnose a particular disease is of great interest. The available methods are multi-staged, with many computational bottlenecks in between. This paper presents an improved end-to-end method of multimodal image classification using deep learning models. We present top research methods developed over the years to improve models trained from scratch and transfer learning approaches. We show that when fully trained, a model can first implicitly discriminate the imaging modality and then diagnose the relevant disease. Our developed models were applied to COVID-19 classification from chest X-ray, CT scan, and lung ultrasound image modalities. The model that achieved the highest accuracy correctly maps all input images to their respective modality, then classifies the disease achieving overall 91.07% accuracy. [ABSTRACT FROM AUTHOR]

Due to false negative results of the real-time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test, the complemental practices such as computed tomography (CT) and X-ray in combination with RT-PCR are discussed to achieve a more accurate diagnosis of COVID-19 in clinical practice. Since radiology includes visual understanding as well as decision making under limited conditions such as uncertainty, urgency, patient burden, and hospital facilities, mistakes are inevitable. Therefore, there is an immediate requirement to carry out further investigation and develop new accurate detection and identification methods to provide automatically quantitative evaluation of COVID-19. In this paper, we propose a new computer-aided diagnosis application for COVID-19 detection using deep learning techniques. A new technique, which receives symmetric X-ray data as the input, is presented in this study by combining Convolutional Neural Networks (CNN) with Ant Lion Optimization Algorithm (ALO) and Multiclass Naïve Bayes Classifier (NB). Moreover, several other classifiers such as Softmax, Support Vector Machines (SVM), K-Nearest Neighbors (KNN) and Decision Tree (DT) are combined with CNN. The promising results of these classifiers are evaluated and presented for accuracy, precision, and F1-score metrics. NB classifier with Ant Lion Optimization Algorithm and CNN produced the best results with 98.31% accuracy, 100% precision and 98.25% F1-score and with the lowest execution time. [ABSTRACT FROM AUTHOR]

Laboratory medicine plays a fundamental role in the detection, diagnosis and management of COVID-19 infection. Recent observations of the morphology of cells circulating in blood found the presence of particular reactive lymphocytes (COVID-19 RL) in some of the infected patients and demonstrated that it was an indicator of a better prognosis of the disease. Visual morphological analysis is time consuming, requires smear review by expert clinical pathologists, and is prone to subjectivity. This paper presents a convolutional neural network system designed for automatic recognition of COVID-19 RL. It is based on the Xception71 structure and is trained using images of blood cells from real infected patients. An experimental study is carried out with a group of 92 individuals. The input for the system is a set of images selected by the clinical pathologist from the blood smear of a patient. The output is the prediction whether the patient belongs to the group associated with better prognosis of the disease. A threshold is obtained for the classification system to predict that the smear belongs to this group. With this threshold, the experimental test shows excellent performance metrics: 98.3% sensitivity and precision, 97.1% specificity, and 97.8% accuracy. The system does not require costly calculations and can potentially be integrated into clinical practice to assist clinical pathologists in a more objective smear review for early prognosis. [ABSTRACT FROM AUTHOR]

In order to understand how these studies are evolving to respond to COVID-19 and to facilitate the containment of COVID-19, this paper accurately extracted the spatial and topic information from the metadata of papers related to COVID-19 using text mining techniques, and with the extracted information, the research evolution was analyzed from the temporal, spatial, and topic perspectives. From a temporal view, in the three months after the emergence of COVID-19, the number of published papers showed an obvious growth trend, and it showed a relatively stable cyclical trend in the later period, which is basically consistent with the development of COVID-19. Spatially, most of the authors who participated in related research are concentrated in the United States, China, Italy, the United Kingdom, Spain, India, and France. At the same time, with the continuous spread of COVID-19 in the world, the distribution of the number of authors has gradually expanded, showing to be correlated with the severity of COVID-19 at a spatial scale. From the perspective of topic, the early stage of COVID-19 emergence, the related research mainly focused on the origin and gene identification of the virus. After the emergence of the pandemic, studies related to the diagnosis and analysis of psychological health, personal security, and violent conflict are added. Meanwhile, some categories are most closely related to the control and prevention of the epidemic, such as pathology analysis, diagnosis, and treatment; epidemic situation and coping strategies; and prediction and assessment of epidemic situation. In most time periods, the majority of studies focused on these three categories. [ABSTRACT FROM AUTHOR]

The Coronavirus disease 2019 (COVID-19) pandemic continues to spread worldwide with over 260 million people infected and more than 5 million deaths, numbers that are escalating on a daily basis. Frontline health workers and scientists diligently fight to alleviate life-threatening symptoms and control the spread of the disease. There is an urgent need for better triage of patients, especially in third world countries, in order to decrease the pressure induced on healthcare facilities. In the struggle to treat life-threatening COVID-19 pneumonia, scientists have debated the clinical use of ionizing radiation (IR). The historical literature dating back to the 1940s contains many reports of successful treatment of pneumonia with IR. In this work, we critically review the literature for the use of IR for both diagnostic and treatment purposes. We identify details including the computed tomography (CT) scanning considerations, the radiobiological basis of IR anti-inflammatory effects, the supportive evidence for low dose radiation therapy (LDRT), and the risks of radiation-induced cancer and cardiac disease associated with LDRT. In this paper, we address concerns regarding the effective management of COVID-19 patients and potential avenues that could provide empirical evidence for the fight against the disease. [ABSTRACT FROM AUTHOR]

Maskne, a newly coined term deriving from the contraction of mask-related acne, is a form of mechanical acne resulting from continuous textile–skin adherence and friction. Prolonged mask use heats up the face environment, thus modifying skin microbiota and sebum production. Although effective prevalence is unknown, since the pandemic began and the prolonged use of masks was extended to the general population, maskne has been a frequent topic of consultation among dermatologists. This term has been successfully introduced into common language, with more than 200,000 hashtags on social media, where it is also possible to find "home remedies" that can worsen this dermatosis. The aim of this paper is to discuss the pathogenesis, address clinicians on the correct differential diagnoses among facial dermatoses, and move towards the correct therapy. [ABSTRACT FROM AUTHOR]

Preventing respiratory failure is crucial in a large proportion of COVID-19 patients infected with SARS-CoV-2 virus pneumonia termed as Novel Coronavirus Pneumonia (NCP). Rapid diagnosis and detection of high-risk patients for effective interventions have been shown to be troublesome. Using a large, computed tomography (CT) database, we developed an artificial intelligence (AI) parameter to diagnose NCP and distinguish it from other kinds of pneumonia and traditional controls. The literature was studied and analyzed from diverse assets which include Scopus, Nature medicine, IEEE, Google scholar, Wiley Library, and PubMed. The search terms used were 'COVID-19', 'AI', 'diagnosis', and 'prognosis'. To strengthen the overall performance of AI in COVID-19 diagnosis and prognosis, we segregated several components to perceive threats and opportunities, as well as their inter-dependencies that affect the healthcare sector. This paper seeks to pick out the crucial fulfillment of factors for AI with inside the healthcare sector in the Indian context. Using critical literature review and experts' opinion, a total of 11 factors affecting COVID-19 diagnosis and prognosis were detected, and we eventually used an interpretive structural model (ISM) to build a framework of interrelationships among the identified factors. Finally, the matrice d'impacts croisés multiplication appliquée á un classment (MICMAC) analysis resulted the driving and dependence powers of these identified factors. Our analysis will help healthcare stakeholders to realize the requirements for successful implementation of AI. [ABSTRACT FROM AUTHOR]

A commercially available isothermal amplification of SARS-CoV-2 RNA was applied to self-collected saliva samples using dry dental cotton rolls, which were held in the mouth for two minutes. Of 212 tests, isothermal amplification yielded three (0.14%) invalid results, 120 (56.6%) positive results and 89 (42%) negative results. Compared to reference RT-PCR assays routinely performed simultaneously on nasopharyngeal swabs, excluding the three invalid isothermal amplification assays and one RT-PCR invalid assay, these figures indicated that 119/123 (96.7%) samples were positive in both methods and 85/85 samples were negative in both methods. Four positive buccal swabs which were missed by the isothermal amplification, exhibited Ct values of 26–34 in reference RT-PCR assays. Positive isothermal amplification detection was achieved in less than 10 min. Supervision of the self-sampling procedure was key to achieve these performances. These data support the proposal to use the protocol reported in this paper, including supervised buccal self-sampling, to screen people suspected of having COVID-19 at the point of care. [ABSTRACT FROM AUTHOR]

No routine laboratory biomarkers perform well enough in diagnosing COVID-19 in isolation for them to be used as a standalone diagnostic test or to help clinicians prioritize patients for treatment. Instead, other diagnostic tests are needed. The aim of this work was to statistically summarise routine laboratory biomarker measurements in COVID-19-positive and -negative patients to inform future work. A systematic literature review and meta-analysis were performed. The search included names of commonly used, routine laboratory tests in the UK NHS, and focused on research papers reporting laboratory results of patients diagnosed with COVID-19. A random effects meta-analysis of the standardized mean difference between COVID-19-positive and -negative groups was conducted for each biomarker. When comparing reported laboratory biomarker results, we identified decreased white blood cell, neutrophil, lymphocyte, eosinophil, and platelet counts; while lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase were elevated in COVID-19-positive compared to COVID-19-negative patients. Differences were identified across a number of routine laboratory biomarkers between COVID-19-positive and -negative patients. Further research is required to identify whether routine laboratory biomarkers can be used in the development of a clinical scoring system to aid with triage of patients. [ABSTRACT FROM AUTHOR]

Artificial intelligence (AI) has shown immense potential to fight COVID-19 in many ways. This paper focuses primarily on AI's role in managing COVID-19 using digital images, clinical and laboratory data analysis, and a summary of the most recent articles published last year. We surveyed the use of AI for COVID-19 detection, screening, diagnosis, the progression of severity, mortality, drug repurposing, and other tasks. We started with the technical overview of all models used to fight the COVID-19 pandemic and ended with a brief statement of the current state-of-the-art, limitations, and challenges. [ABSTRACT FROM AUTHOR]

The current coronavirus disease 2019 (COVID-19) outbreak is considered as one of the biggest public health challenges and medical emergencies of the century. A global health emergency demands an urgent development of rapid diagnostic tools and advanced therapeutics for the mitigation of COVID-19. To cope with the current crisis, nanotechnology offers a number of approaches based on abundance and versatile functioning. Despite major developments in early diagnostics and control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is still a need to find effective nanomaterials with low cost, high stability and easy use. Nanozymes are nanomaterials with innate enzyme-like characteristics and exhibit great potential for various biomedical applications such as disease diagnosis and anti-viral agents. Overall the potential and contribution of nanozymes in the fight against SARS-CoV-2 infection i.e., rapid detection, inhibition of the virus at various stages, and effective vaccine development strategies, is not fully explored. This paper discusses the utility and potential of nanozymes from the perspective of COVID-19. Moreover, future research directions and potential applications of nanozymes are highlighted to overcome the challenges related to early diagnosis and therapeutics development for the SARS-CoV-2. We anticipate the current perspective will play an effective role in the existing response to the COVID-19 crisis. [ABSTRACT FROM AUTHOR]

Considering the current pandemic, caused by the spreading of the novel Coronavirus disease, there is the urgent need for methods to quickly and automatically diagnose infection. To assist pathologists and radiologists in the detection of the novel coronavirus, in this paper we propose a two-tiered method, based on formal methods (to the best of authors knowledge never previously introduced in this context), aimed to (i) detect whether the patient lungs are healthy or present a generic pulmonary infection; (ii) in the case of the previous tier, a generic pulmonary disease is detected to identify whether the patient under analysis is affected by the novel Coronavirus disease. The proposed approach relies on the extraction of radiomic features from medical images and on the generation of a formal model that can be automatically checked using the model checking technique. We perform an experimental analysis using a set of computed tomography medical images obtained by the authors, achieving an accuracy of higher than 81% in disease detection. [ABSTRACT FROM AUTHOR]

Coronavirus disease 2019 (COVID-19), due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become an epidemiological threat and a worldwide concern. SARS-CoV-2 has spread to 210 countries worldwide and more than 6,500,000 confirmed cases and 384,643 deaths have been reported, while the number of both confirmed and fatal cases is continually increasing. COVID-19 is a viral disease that can affect every age group—from infants to the elderly—resulting in a wide spectrum of various clinical manifestations. COVID-19 might present different degrees of severity—from mild or even asymptomatic carriers, even to fatal cases. The most common complications include pneumonia and acute respiratory distress syndrome. Fever, dry cough, muscle weakness, and chest pain are the most prevalent and typical symptoms of COVID-19. However, patients might also present atypical symptoms that can occur alone, which might indicate the possible SARS-CoV-2 infection. The aim of this paper is to review and summarize all of the findings regarding clinical manifestations of COVID-19 patients, which include respiratory, neurological, olfactory and gustatory, gastrointestinal, ophthalmic, dermatological, cardiac, and rheumatologic manifestations, as well as specific symptoms in pediatric patients. [ABSTRACT FROM AUTHOR]

At the time of writing, the COVID-19 infection is spreading rapidly. Currently, there is no vaccine or treatment, and researchers around the world are attempting to fight the infection. In this paper, we consider a diagnosis method for COVID-19, which is characterized by a very rapid rate of infection and is widespread. A possible method for avoiding severe infections is to stop the spread of the infection in advance by the prompt and accurate diagnosis of COVID-19. To this end, we exploit a group testing (GT) scheme, which is used to find a small set of confirmed cases out of a large population. For the accurate detection of false positives and negatives, we propose a robust algorithm (RA) based on the maximum a posteriori probability (MAP). The key idea of the proposed RA is to exploit iterative detection to propagate beliefs to neighbor nodes by exchanging marginal probabilities between input and output nodes. As a result, we show that our proposed RA provides the benefit of being robust against noise in the GT schemes. In addition, we demonstrate the performance of our proposal with a number of tests and successfully find a set of infected samples in both noiseless and noisy GT schemes with different COVID-19 incidence rates. [ABSTRACT FROM AUTHOR]

Graphene-based materials are intriguing nanomaterials with applications ranging from nanotechnology-related devices to drug delivery systems and biosensing. Multifunctional graphene platforms were proposed for the detection of several typical biomarkers (i.e., circulating tumor cells, exosomes, circulating nucleic acids, etc.) in liquid biopsy, and numerous methods, including optical, electrochemical, surface-enhanced Raman scattering (SERS), etc., have been developed for their detection. Due to the massive advancements in biology, material chemistry, and analytical technology, it is necessary to review the progress in this field from both medical and chemical sides. Liquid biopsy is considered a revolutionary technique that is opening unexpected perspectives in the early diagnosis and, in therapy monitoring, severe diseases, including cancer, metabolic syndrome, autoimmune, and neurodegenerative disorders. Although nanotechnology based on graphene has been poorly applied for the rapid diagnosis of viral diseases, the extraordinary properties of graphene (i.e., high electronic conductivity, large specific area, and surface functionalization) can be also exploited for the diagnosis of emerging viral diseases, such as the coronavirus disease 2019 (COVID-19). This review aimed to provide a comprehensive and in-depth summarization of the contribution of graphene-based nanomaterials in liquid biopsy, discussing the remaining challenges and the future trend; moreover, the paper gave the first look at the potentiality of graphene in COVID-19 diagnosis. [ABSTRACT FROM AUTHOR]

Background: The current outbreak of COVID-19 infection, which started in Wuhan, Hubei province, China, in December 2019, is an ongoing challenge and a significant threat to public health requiring surveillance, prompt diagnosis, and research efforts to understand a new, emergent, and unknown pathogen and to develop effective therapies. Despite the increasing number of published studies on COVID-19, in all the examined studies the lack of a well-defined pathophysiology of death among patients who died following COVID-19 infection is evident. Autopsy should be considered mandatory to define the exact cause of death, thus providing useful clinical and epidemiologic information as well as pathophysiological insights to further provide therapeutic tools. Methods: A literature review was performed on PubMed database, using the key terms: "COVID-19", "nCov 19", and "Sars Cov 2". 9709 articles were retrieved; by excluding all duplicated articles, additional criteria were then applied: articles or abstracts in English and articles containing one of the following words: "death", "died", "comorbidity", "cause of death", "biopsy", "autopsy", or "pathological". Results: A total of 50 articles met the inclusion criteria. However, only 7 of these studies reported autopsy-based data. Discussion: The analysis of the main data from the selected studies concerns the complete analysis of 12,954 patients, of whom 2269 died (with a mortality rate of 17.52%). Laboratory confirmation of COVID-19 infection was obtained in all cases and comorbidities were fully reported in 46 studies. The most common comorbidities were: cardiovascular diseases (hypertension and coronary artery disease), metabolic disorders (diabetes, overweight, or obesity), respiratory disorders (chronic obstructive pulmonary disease), and cancer. The most common reported complications were: acute respiratory distress syndrome (ARDS), acute kidney injury, cardiac injury, liver insufficiency, and septic shock. Only 7 papers reported histological investigations. Nevertheless, only two complete autopsies are described and the cause of death was listed as COVID-19 in only one of them. The lack of postmortem investigation did not allow a definition of the exact cause of death to determine the pathways of this infection. Based on the few histopathological findings reported in the analyzed studies, it seems to be a clear alteration of the coagulation system: frequently prothrombotic activity with consequent thromboembolism was described in COVID-19 patients. As a scientific community, we are called on to face this global threat, and to defeat it with all the available tools necessary. Despite the improvement and reinforcement of any method of study in every field of medicine and science, encouraging the autopsy practice as a tool of investigation could also therefore, help physicians to define an effective treatment to reduce mortality. [ABSTRACT FROM AUTHOR]